Generic Name and Formulations:
Zaleplon 5mg, 10mg; caps; contains tartrazine.
Indications for SONATA:
Short-term treatment of insomnia.
Usually 10mg at bedtime (at least 4hrs before becoming active again); max 20mg. Mild-to-moderate hepatic impairment, elderly, debilitated, concomitant cimetidine, or low weight patients: 5mg; max 10mg. Max 1month/℞. Effect delayed if taken with high-fat/heavy meals.
Severe hepatic impairment: not recommended. Compromised respiratory function, mild-to-moderate hepatic impairment, debilitated: monitor closely. Depression. Behavioral changes. Suicidal tendencies. Drug or alcohol abuse. Conditions that affect metabolism or hemodynamic response. Write ℞ for smallest practical amount. Elderly. Debilitated. Labor & delivery. Pregnancy (Cat.C), nursing mothers: not recommended.
Potentiates CNS depression with alcohol, other CNS depressants. Efficacy may be compromised by drug(s) that induce CYP3A4. May be potentiated by drugs that inhibit aldehyde oxidase (eg, cimetidine, possibly diphenhydramine). May be antagonized by promethazine.
CNS effects, complex sleep-related behaviors (eg, sleep-driving), GI upset, abdominal pain, migraine; anaphylaxis, angioedema, others (see full labeling).
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA Fast-Tracks Treatment for Autism Spectrum Disorder
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics